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Abstract
Background: Several injectable materials have been shown to preserve or improve cardiac function as well as prevent or
slow left ventricular (LV) remodeling post-myocardial infarction (MI). However, it is unclear as to whether it is the structural
support or the bioactivity of these polymers that lead to beneficial effects. Herein, we examine how passive structural
enhancement of the LV wall by an increase in wall thickness affects cardiac function post-MI using a bio-inert, non-
degradable synthetic polymer in an effort to better understand the mechanisms by which injectable materials affect LV
remodeling.
Methods and Results: Poly(ethylene glycol) (PEG) gels of storage modulus G9=0.560.1 kPa were injected and polymerized
in situ one week after total occlusion of the left coronary artery in female Sprague Dawley rats. The animals were imaged
using magnetic resonance imaging (MRI) at 761 day(s) post-MI as a baseline and again post-injection 4964 days after MI.
Infarct wall thickness was statistically increased in PEG gel injected vs. control animals (p,0.01). However, animals in the
polymer and control groups showed decreases in cardiac function in terms of end diastolic volume, end systolic volume and
ejection fraction compared to baseline (p,0.01). The cellular response to injection was also similar in both groups.
Conclusion: The results of this study demonstrate that passive structural reinforcement alone was insufficient to prevent
post-MI remodeling, suggesting that bioactivity and/or cell infiltration due to degradation of injectable materials are likely
playing a key role in the preservation of cardiac function, thus providing a deeper understanding of the influencing
properties of biomaterials necessary to prevent post-MI negative remodeling.
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Introduction
Progressive left ventricular (LV) remodeling occurs after
myocardial infarction (MI), and while remodeling can be
beneficial initially, over time it can become maladaptive leading
to LV dysfunction [1]. With 5.8 million people suffering from
heart failure (HF), treatment of negative LV remodeling after MI,
the leading cause of HF, is a pressing clinical need [2]. Coagulative
necrosis following MI initiates a cascade of events characterized by
myocyte necrosis and their eventual replacement by fibrotic scar
tissue. Necrosis of the myocytes triggers an inflammatory response
leading to activation of matrix metalloproteinases [3] that cause a
breakdown of the extracellular matrix, which results in myocyte
slippage and infarct expansion. At the same time fibroblast
proliferation occurs, leading to deposition of collagen and the
formation of scar tissue. Concurrent TGF-b1 mediated transfor-
mation of fibroblast to myofibroblasts leads to deposition of type I
and III collagen and scar tissue formation from subsequent
collagen cross-linking [1]. Ventricular wall thinning and dilatation
also occurs leading to an increase in wall stress, and ultimately
resulting in heart failure [1,4,5].
Various injectable biomaterials have been investigated as
potential acellular treatments to prevent or reverse this downward
spiral of adverse LV remodeling [6]. Collagen [7], fibrin [8],
chitosan [9], small intestinal submuscosa (SIS) [10], and a
collagen-matrigel blend [11] as well as a few degradable synthetic
materials [12,13,14] have shown either an improvement or
maintenance of cardiac function in terms of ejection fraction or
fractional shortening. Injection of alginate has been shown to
cause a decrease in LV diastolic area and systolic area [15,16]
while fibrin [17], hyaluronic acid (HA) [18], SIS [10] and a
synthetic thermoresponsive polymer [14] reduced infarct size.
Injection of biomaterials such as collagen [19], matrigel [19],
fibrin [17,19], alginate [20], chitosan [9], self-assembling nanofi-
bers [21], SIS [10], and a degradable thermoresponsive polymer
[13] have also increased neovasculature. Though most injectable
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remodeling, to date, the mechanisms behind this improvement are
unknown.
It has been shown that myocardial infarction can lead to an
increase in wall stress due to changes in wall curvature and
thickness in accordance with Laplace’s Law, which states that
wall stress is directly proportional to the pressure and radius, and
inversely proportional to thickness. Wall thinning due to
infarction can increase wall stress, and may contribute to border
zone expansion and progression of negative LV remodeling [22].
Hence, it has been hypothesized that injectable materials may
affect the passive structural properties of the wall by increasing
infarct wall thickness and hence reducing local LV wall stress
[6,23]. This decrease in LV wall stress is thought to protect the
vulnerable myocardium from stress induced apoptosis and infarct
expansion, thus preventing pathological LV remodeling and
decline in cardiac function [23]. On the other hand, injectable
materials have also been shown to elicit cell infiltration
[19,21,24] and neovascularization [19] in the affected area.
This leads to the alternate hypothesis that the bioactivity of
materials, such as inherent cell adhesion domains or angiogenic
degradation products, and/or cell infiltration upon degradation
of these materials are playing an important role in prevention of
adverse LV remodeling and improvement of cardiac function
[6,25,26].
The aim of this study was to begin to understand the
mechanisms by which injectable materials preserve cardiac
function and prevent negative LV remodeling post-MI by
decoupling bioactivity from the structural effects of an injectable
polymer. Herein, we utilized an injectable, bio-inert, non-
degradable polymer, polyethylene glycol (PEG), along with
experimental parameters similar to those employed in previous
studies aimed at assessing the effects of injectable biomaterials on
LV remodeling and cardiac function. PEG is a well established
synthetic polymer that is known to be non-toxic [27] and bio-inert,
thus preventing protein and cell adhesion [27,28,29,30]. We
demonstrate that passive structural intramyocardial support by
itself does not prevent negative LV remodeling or maintain
cardiac function, suggesting that other mechanisms such as
bioactivity and/or cell infiltration seen with degradable materials
likely play a dominant role in the mitigation of LV remodeling and
preservation of cardiac function.
Materials and Methods
All experiments in this study were conducted in accordance with
the guidelines established by the Institutional Animal Care and
Use Committee at the University of California, San Diego and the
American Association for Accreditation of Laboratory Animal
Care and were approved by the Institutional Animal Care and Use
Committee at UCSD (A3033-01). All efforts were made to
minimize any pain and suffering felt by the animals.
PEG hydrogel preparation
PEG hydrogels were prepared by mixing solutions of 4-arm
polyethylene glycol-amide-succinimidyl glutarate (PEG-ASG)
(Sunbio, Anyang City, South Korea, MW 20,000) and trilysine
(Sigma-Aldrich, St. Louis, MO) to create PEG hydrogels of desired
stiffness at room temperature by chemical crosslinking [31].
Optimal concentrations of PEG-ASG and trilysine were experi-
mentally determined to generate gels of stiffness similar to that of
commonly injected biomaterials. Equal volumes of 100 mg/ml
PEG-ASG in pH 4.0 phosphate buffer and 0.5–2 mg/ml trilysine
in pH 8.2 borate buffer were mixed together to prepare the
hydrogels. For in-vivo injections of PEG, the solutions were mixed
together and injected prior to gelation.
Mechanical testing
Material properties in terms of the storage modulus (G9) and loss
modulus (G0) were determined using a parallel plate rheometer
(TA Instruments AR-2000) as previously reported [32,33]. Briefly,
gels were placed between two parallel plates of the rheometer and
compressed to a normal force between 0.2–0.3 N, to avoid
slipping. A strain sweep (0.0001 to 10%) was performed at a
constant frequency of 1 Hz to confirm that the measurements
were within the linear viscoelastic region. 1% constant strain was
used for subsequent frequency sweeps (0.01 to 10 Hz) using a
logarithmic scale, taking 5 points per decade. All measurements
were taken in triplicate and reported as mean 6 SEM at a
frequency of 1 Hz.
Rat total occlusion model
Left coronary artery total occlusion was performed on female
Sprague Dawley rats (225–250 g) under aseptic conditions.
Animals were anesthetized using 5% isoflurane, intubated and
maintained at 2.5% isoflurane for the surgical procedure. The
animals were ventilated using a respirator at 75 breaths/minute.
The heart was exposed using a left anterior thoracotomy, and the
artery was ligated using a 6-0 silk suture at 1–2 mm below the left
atrial appendage as previously reported [34]. The chest was closed
and the animals were allowed to recover. ECG was continuously
monitored for detection of arrhythmias, and atropine 150 to
200 ml (0.54 mg/ml) was administered I.P. if needed. Buprenor-
phine was administered I.P. at 5 mg/kg to prevent post-operative
pain and Ringer’s Lactate (3 cc) was given I.P. to the animals to
prevent dehydration.
Echocardiography
Echocardiography was performed 461 day(s) post-MI to screen
for the presence of an infarct. Animals were anesthetized using 5%
isoflurane for 30 seconds and then maintained at 1% isoflurane for
the imaging procedure. Parasternal long axis and short axis images
were obtained using a Philips, Sonos 5500 system with a 15 MHz
transducer. Qualitative assessment of infarction size was rendered
at the time of imaging using both planes. Animals with either no
MI or very small MI (less than 15% of the LV perimeter in the
long axis plane) were excluded from the study prior to injections.
Injection surgery
The animals were randomized 961 day(s) after MI, and
injected with either 100 ml of PEG hydrogel or saline (control). An
incision was made between the fourth and fifth ribs, the
anterolateral portion of the heart was exposed, and an injection
of polymer or saline was administered using a 27 G needle into the
infarct wall. Presence of the injection was verified by temporary
discoloration of the tissue. The chest was then closed and the
animal was allowed to recover. To prevent post-operative pain in
the animals, buprenorphine was administered at 5 mg/kg.
Magnetic resonance imaging
Magnetic Resonance (MR) imaging was used for quantitative
assessment of the injected gel on cardiac function. Animals were
scanned at 761 day(s) post-MI, as a baseline measurement, and
again at 4964 days after MI to assess post-treatment effects on
remodeling and cardiac function. A 7T Bruker Horizontal Bore
scanner and Bruker single tuned quadrature Transmit/Receive
volume coil were used for all measurements. Anatomical cine
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(FLASH) sequence as previously reported [35]. MR parameters
were set to TR=7.7 ms, TE=1.28 ms, flip angle=15u and 4–6
averages per slice. All slices were 1 mm in thickness, had a field of
view of 50 mm650 mm and were contained in a data matrix of
2566256 pixels. For each slice, 25 frames were taken through the
cardiac cycle to capture end diastolic and end systolic images.
Animals were anesthetized using 1.5–2% isoflurane and the heart
rate, ECG and respiration rate were monitored continuously.
The long axis of the heart was identified and 10–12 short axis
slices from apex to base were acquired at 1 mm increments.
ImageJ was used to trace the endocardial boundary at end
diastole (ED) and end systole (ES) on each short axis slice.
Simpson’s method was used to determine the end diastolic
volume (EDV) and end systolic volume (ESV). Ejection fraction
(EF) was calculated as [(EDV-ESV)/EDV]6100 similar to
previous methods [36].
Finite element modeling
In order to visually represent LV dilatation and wall thickness
pre and post-injection, finite element analysis was used to generate
geometric models of the LV at ED and ES using prolate spheroidal
bi-cubic Hermite finite element surface meshes [35]. Meshes were
fit to the endocardial and epicardial boundary points determined
from the MRI cine images. The boundary points were fit using a
least squares minimization in the l coordinate direction with
bicubic Hermite interpolation. The 40 element mesh was refined
to 340 elements and was converted to Cartesian coordinates so
that the long axis of the heart aligned with the X- axis and the
septum was bisected by the Y-axis.
Histology and immunohistochemisty
Animals were sacrificed 24 hours after post-treatment MR
imaging (,49 days post-MI) by an IP injection of Fatal Plus
(sodium pentobarbital, 936 mg/kg). Hearts were immediately
excised and fresh frozen in Tissue-Tek O.C.T. freezing com-
pound. Hearts were sectioned into 10 mm slices and slides taken
every 0.4 mm were stained with hematoxylin and eosin (H&E) to
visualize the polymer injection. Images were taken using a Carl
Zeiss Observer D.1 and analyzed using AxioVision software.
A pathologist qualitatively assessed inflammatory response
[37,38,39] to the injection in the infarct, border zone and remote
tissue in the H&E stained sections at mid-infarct. Macrophages
were identified using an anti-rat CD68 primary antibody [40].
Tissue sections were incubated with 1:50 dilution of mouse anti-rat
CD68 and subsequently incubated with horseradish peroxidase
(HRP) conjugated goat anti-mouse IgG (1:100 dilution). The HRP
was visualized by incubation with diaminobenzidine (DAB) for
10 minutes. Wall thickness was calculated using 3 mid-infarct
slides, averaging 5 equally spaced measurements along the infarct
wall in each slide. Infarct size was calculated using H&E stained
sections by calculating the average of the ratio of the endocardial
infarct length to the endocardial circumference and the ratio of the
epicardial infarct length to the epicardial circumference over three
slides evenly spaced through the infarct as previously shown [41].
To assess arteriole density, immunohistochemistry staining was
done on three slides evenly spaced through the polymer region or
infarct for each of the PEG and saline injected hearts respectively,
according to previously described methods [17,20,24]. Briefly, the
sections were fixed with acetone, incubated with anti-smooth
muscle actin antibody and then stained with Alexa Fluor 568 anti-
mouse antibody. Vessels in the range of 10 mm to 100 mm in the
infarct were quantified with Axiovision.
Statistical analysis
Two-tailed Students’ t-test was used for infarct wall thickness
and arteriole density analyses. Differences between baseline and
post-treatment groups with MRI analysis were assessed using a
paired two-tailed t-test. All measurements were reported mean 6
SEM. Significance was accepted at p,0.05.
Results
PEG hydrogel mechanical characterization
To create a PEG hydrogel with desired mechanical properties,
the amount of trilysine crosslinker (0.5 mg/ml to 2 mg/ml) was
varied. A strain sweep test and a frequency sweep test were
performed to generate mechanical spectra of the gels. We sought
to test a polymer with similar mechanical properties to commonly
injected materials to better delineate between structural effects and
bioactivity. A storage modulus (G9) of 0.560.1 kPa (trilysine
1 mg/ml) (Figure 1) was selected as it mimicked the mechanical
properties of commonly injected polymers [42,43]. As expected
the G9 is independent of frequency and G0 (loss modulus) is weakly
dependent on frequency [33,44].
LV geometry and cardiac function
In-vivo studies were performed to assess the effect of the bio-
inert, non-degradable PEG hydrogel on wall thickness, EF, EDV
and ESV. All animals underwent a surgery to induce MI. After
screening echocardiography, 17 out of 33 animals were included
in the study based on presence of a sizable infarct. One additional
animal died during intubation prior to injection. Sixteen animals
therefore underwent either polymer (n=8) or saline (n=8)
injections. 100% of the animals survived the injection surgery;
however, 3 animals were removed from functional analysis, 2
animals from the saline group and 1 from the polymer group, due
to inconsistent gating during MR imaging. These animals were
included in the histological analysis. One animal from the polymer
group was excluded from the entire study due to insufficient
polymer injection based on histology. In addition, infarct size was
not different in the PEG (44.1%62.8%) and saline (48.0%62.8%)
injected animals (p=0.336).
Animals injected with the PEG hydrogel showed a significantly
thicker infarct wall in comparison to saline injected animals
(p=0.006) as seen via histological analysis (Figure 2). Despite the
increase in wall thickness, analysis of the MR images showed a
steady decline in cardiac function and expansion of LV volume by
comparing values pre- and post-treatment (Figure 3). At 7 weeks
there was a significant increase in LV EDV (p=0.0016) and ESV
(p=0.0008), as well as a decrease in EF (p=0.006) in the polymer
group. As expected in the saline control group, LV EDV
Figure 1. Mechanical spectra. Typical mechanical spectra for a
hydrogel formed by crosslinking of 4-arm PEG-ASG (100 mg/ml) and
trilysine (1 mg/ml).
doi:10.1371/journal.pone.0021571.g001
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corresponding decline in EF (p=0.005). The heart rate of the
animals was continuously monitored during the imaging process
and was statistically similar between the PEG and saline injected
groups: 278617 beats/min (PEG pre-injection) and 28168 beats/
min (PEG post-injection); 271614 beats/min (saline pre-injection)
and 28568 beats/min (saline post-injection). The ECG was
carefully monitored during the time of image acquisition. There
were no noticeable arrhythmias.
As a 3-D visual representation of the overall effect of polymer
injection, finite element models were generated using the
endocardial and epicardial boundaries traced from the MR
images in ED (Figure 4). The overall change in infarcted LV free
wall thickness is seen pre- and post-injection (Figure 4, arrows).
The hearts injected with the PEG hydrogel demonstrated a
regional increase in wall thickness in the infarcted area while the
saline injected hearts showed a thinning of the infarct region at 7
weeks. Dilation of ventricle is clearly depicted by enlargement of
the LV lumen at 7 weeks as compared to baseline.
Cellular response to injection
As expected there was a very thin layer of encapsulation around
the PEG injection region; however, there were no apparent
differences in the inflammatory response (macrophages, fibroblasts,
foreign body giant cells) between the polymer and saline injected
animals in the infarct, border zone or remote myocardium as
expected due to the bio-inert properties of PEG [27,28,29,30]
(Figure 5A & 5B). To further confirm this assessment, we examined
the tissue for presence of CD68
+ macrophages and confirmed that
there was no accumulation of macrophages in PEG injected hearts
(Figure 5C & 5D). Immunohistochemistry was performed on
multiple sections through the hearts to assess the effect of polymer
injection on potential neovascularization in the infarct area. There
was no significant difference in arteriole density for vessel diameters
ranging between 10 mm and 100 mm in the infarct region of the
polymer (1962 arterioles/mm
2) and saline (2062 arterioles/mm
2)
injected hearts, or when vessels were binned as ,10 mm, between
10 mm and 25 mm, between 25 mma n d5 0mm and between 50 mm
and 100 mm, suggesting that polymer injection did not promote
increased vessel formation (Figure 6).
Discussion
To date, the exact mechanism by which injectable materials
lead to an improvement in cardiac function is unknown. As most
injectable biomaterials cause an increase in infarct wall thickness,
some have hypothesized that this passive structural enhancement
alone may have therapeutic benefit [6,23]. After MI, there is
typically a thinning of the myocardial wall and replacement with
scar tissue. According to the Law of Laplace, this thinning can
cause an increase in wall stress that can cause infarct expansion
and apoptosis of the myocytes, which in turn can lead to dilation of
LV and subsequent HF [4,23]. Thus, it has been proposed that use
of an injectable material to increase wall thickness may lead to a
decrease in wall stress and hence prevent adverse LV remodeling
[23]. Alternatively, bioactivity or degradation properties of
biomaterials may lead to the beneficial effects of these materials
in the post-MI setting. The majority of biomaterials that have been
examined to date are degradable materials that allow for cell
infiltration, as well as biopolymers that have inherent bioactivity.
In an effort to begin to understand the mechanisms behind which
injectable polymers improve cardiac function, we chose to
examine a bio-inert, non-degradable synthetic polymer, PEG, to
decouple a material’s structural effects from its bioactivity. We
chose a compliant gel that mimicked the mechanical properties of
commonly injected polymers. Results from this study indicate that
injection of PEG leads to an increase in infarct wall thickness,
consistent with what has previously been seen with other materials
[7,8,14,15]. However, this was insufficient to prevent negative LV
remodeling or improve cardiac function as determined through
MRI. A strictly structural enhancement of the LV wall may
therefore be insufficient for preservation or improvement of
cardiac function and/or slowing the progression of negative LV
remodeling after MI. These results therefore indicate that other
properties of injectable biomaterials may be playing an important
role in maintenance or enhancement of function post-MI.
In this study, we show that injection of the non-degradable PEG
does not induce post-MI neovascularization, nor does it increase
cell infiltration in general. In contrast, many previously injected
materials that have shown improvement in cardiac function
display increased neovascularization, possibly restoring the blood
supply to the affected area and preventing negative LV remodeling
[9,19,21]. The increase in new vessel formation could be due to
bioactive components of the materials such as angiogenesis
inducing degradation products (e.g. Fibrin fragment E [45] and
peptide fragment hepIII of collagen IV [46]) Unlike PEG, most of
these biomaterials also have integrin binding sites that are
important for the influx of cells, such as endothelial cells and
myofibroblasts [47]. Huang et al have shown that injection of
collagen in the infarct induced significant myofibroblast infiltra-
Figure 2. Histological assessment. Histological assessment of polymer and saline injections 7 weeks after MI. Representative slides stained with
H&E: (A) PEG hydrogel (G9=0.5 kPa) injected in infarct region and (B) saline injected in infarct region. (C) Infarct wall thickness at 7 weeks post-MI.
Wall thinning was prevented in the PEG injected group compared to the control. (*p,0.01, PEG: n=7, saline: n=8 ) Photomicrographs are taken at
10X and scale bars are 1 mm. PEG area outlined with dotted line and demarcated by an asterisk (*).
doi:10.1371/journal.pone.0021571.g002
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migration in fibrin and matrigel injected hearts [19]. It has been
shown that the contractile nature of myofibroblasts may lead to
infarct size reduction and mitigation of infarct expansion, leading
to overall improvement in function [48]. In addition to
biopolymers, beneficial effects with a few degradable synthetic
polymers that allow for cell influx have also been observed [13].
Therefore, cell infiltration due to degradation of injected polymers
might be a potential mechanism by which these materials elicit
salutatory effects. Though this effect with biopolymers is likely a
result of their inherent bioactivity, these materials have also been
shown to degrade in the range of 1–6 weeks [9,17,19]. While most
of these infiltrating cells cannot restore function to the damaged
area, it is possible that the migration of these cells in a timely
manner provides beneficial paracrine effects necessary to prevent
or lessen infarct scar expansion that is commonly seen post-MI.
While most materials have been degradable, there is one report
of a synthetic non-degradable polymer being used for treatment of
MI; Dobner et al [49], injected a non-degradable PEG in the
infarct immediately post-MI and showed that there was temporary
retardation of LV remodeling at early time points, but not at later
time points. However, the progression of LV remodeling at later
time points is aligned with the presented results. It is challenging to
make a direct comparison between this study and the presented
work as the material properties of the PEG gel were not
characterized, and the PEG was injected at a different time point.
An additional study has also examined the effects of mechanical
properties of materials in an MI setting. Ifkovits et al [18],
investigated the effect of mechanical modulation of injectable HA
hydrogels on LV remodeling and cardiac function in an ovine MI
model, finding a smaller infarct area in animals injected with the
higher mechanical modulus HA. In that study, the HA spread
more interstitially through the infarct, which could have
contributed to the differences seen in the results of the presented
work and the study performed by Ifkovits et al. However, similar to
the results presented here, there was a reduction in ejection
fraction in all groups compared to baseline. Furthermore, in a
study by Garbern et al, a pH sensitive, temperature responsive
synthetic polymer was injected with or without the addition of
bFGF in a rodent infarct model. The control group injected with
polymer alone increased infarct wall thickness, yet showed a steady
decline in fractional shortening comparable to that of the saline
injected control, indicating the polymer injection did not improve
cardiac function [50]. While the polymer was designed to degrade,
it did not degrade over the course of the study, thus providing
additional evidence that degradation may be a key biomaterial
parameter for preserving or improving cardiac function post-MI.
In the present study, MRI was the imaging modality of choice.
It is well established that MRI is the gold standard for cardiac
Figure 3. Cardiac function. Comparison of cardiac function baseline
(1 week post-MI, pre-injection) and post-treatment (7 weeks post-MI) in
PEG (0.5 kPa) injected and saline injected groups. (A) Ejection fraction.
(B) End diastolic volume. (C) End systolic volume. Statistical significance
determined using paired two-tailed t-test between pre and post-
injection groups. (*p,0.01 PEG compared to baseline, 1 p,0.01 saline
compared to baseline, PEG: n=6, saline: n=6).
doi:10.1371/journal.pone.0021571.g003
Figure 4. 3-D representation of the LV. Finite element represen-
tation of the LV pre and post-injection in both PEG and saline injected
groups. Arrow denotes region of infarction. Infarct wall thickening is
seen in the PEG injected heart while infarct wall thinning is depicted in
the saline injected heart compared to baseline. Also note the dilation of
LV lumen pre and post-injection in both groups.
doi:10.1371/journal.pone.0021571.g004
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measurement of cardiac function after injection of a biomaterial.
Measurements are made at the level of the papillary muscles that
function as an anatomical marker. In the commonly used total
occlusion MI model, the anteroapical portion of the heart is most
severely affected. The effects of LV dilatation and systolic bulging
are thought to be most pronounced in this region. It is possible
that by taking measurements at one level the effect of LV
dilatation distal to the papillary muscles is overlooked and local
effects are being underemphasized. However, using MRI we were
able to determine the overall effect of the polymer injection.
As elucidated here, there may be various factors that are
potentially contributing to the beneficial effect seen with injectable
materials post-MI. In order to better understand the role of
biomaterials in MI treatment and compare our findings to
previous work, the PEG polymer used in this study was specifically
engineered to have properties similar to other previously examined
injectable biomaterials. Moreover, we mimicked common study
parameters such as the timing of injection and the injection
volume. There are however some differences and limitations to
our findings. For example, this PEG gels rapidly upon injection
limiting the interstitial spread of the material, allowing it to serve
as a bulk filler and partial wall replacement. One potential
limitation may be the inability of the polymer bolus to distribute
through the entire area of the infarct as seen with external LV
restraints [53]. This inhomogeneity in spread could lead to
regional abnormalities in function as well as allow for infarct
expansion in regions where the polymer is not present. Moreover,
Figure 5. Inflammatory response. Inflammatory response in polymer and saline injected hearts 7 weeks after MI. (A) PEG injected heart (inset
shows high magnification image of PEG region showing no cell infiltration in the polymer, scale bar 20 mm) (B) saline injected heart. Scale bars are
100 mm. PEG area is demarcated by an asterisk (*). CD68 stained macrophages in (C) PEG injected heart (D) saline injected heart. PEG area outlined
with a dotted line. Scale bars are 20 mm.
doi:10.1371/journal.pone.0021571.g005
Figure 6. Arteriole density. Arteriole density assessment in polymer and saline injected hearts 7 weeks after MI. (A, B) Representative slides with
staining for smooth muscle actin. (A) Arterioles in infarct region of PEG injected animals. PEG area outlined with dotted line and demarcated by an
asterisk (*). (B) Arterioles in infarct region of saline injected animals. Scale bars are 100 mm. (C) Arteriole density (vessel diameter between 10 mm and
100 mm) at 7 weeks post-MI. ( p=0.80, PEG: n=6, saline: n=8 ).
doi:10.1371/journal.pone.0021571.g006
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infarcted LV that negates any structural support provided by the
material injection. In larger animals, multiple injections can ensure
more homogeneous spread of material, although 100% coverage
of the wall would still not be achievable. Despite the single
injection in the majority of rodent experiments, injection of
biomaterials have still improved or preserved cardiac function. In
addition to injection spread, timing of injection may also be an
important parameter. While some may argue at one week post MI
the initial expansion of the ventricle has already occurred, most
previous studies injected material in the infarct approximately 1
week post-infarction [7,8,9,15,17,19,54]. Injection at this time
point also represents greater clinical translatability due to fear of
ventricular rupture at earlier time points. In the literature, volumes
of 50 mL to 150 mL have been injected in rat hearts
[7,8,9,15,17,19,49,54,55,56,57], hence 100 mL injection volume
was selected as it falls in this range and is the volume used most
frequently in biomaterial injection studies.
In conclusion, passive structural enhancement by injection of a
synthetic, non-degradable polymer into a developing infarct did
not improve global cardiac function and was insufficient to alter
post-MI remodeling, thereby suggesting that the bioactivity and/
or cell infiltration seen with degradable materials may likely play
an important role in preserving cardiac function. The results of
this study provide additional insight on the important and
influencing properties of biomaterials necessary for preventing
post-MI negative remodeling. Furthermore, this study highlights
the need for further studies that closely examine biomaterial
parameters in order to guide the design of enhanced biomaterials
therapies for MI.
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